AR111501A2 - PHARMACEUTICAL COMPOSITION OF PHENOFIBRATE AND METHOD TO PREPARE IT - Google Patents
PHARMACEUTICAL COMPOSITION OF PHENOFIBRATE AND METHOD TO PREPARE ITInfo
- Publication number
- AR111501A2 AR111501A2 ARP170101422A ARP170101422A AR111501A2 AR 111501 A2 AR111501 A2 AR 111501A2 AR P170101422 A ARP170101422 A AR P170101422A AR P170101422 A ARP170101422 A AR P170101422A AR 111501 A2 AR111501 A2 AR 111501A2
- Authority
- AR
- Argentina
- Prior art keywords
- surface stabilizer
- fenofibrate
- weight
- fenofibrate nanoparticles
- nanoparticles
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Una composición farmacéutica de fenofibrato para administración oral, caracterizada porque comprende: (i) nanopartículas de fenofibrato que tienen un tamaño de partícula efectivo promedio inferior a 300 nm; (ii) un estabilizador de superficie adsorbido sobre la superficie de las nanopartículas de fenofibrato; en donde las nanopartículas de fenofibrato están presentes en una cantidad de 99,5% a 0,001% en peso, basada en el peso combinado total de las nanopartículas de fenofibrato y un estabilizador de superficie; en donde el estabilizador de superficie está presente en una cantidad seleccionada entre 0,5% y 99,999% en peso, basada en el peso seco combinado total de las nanopartículas de fenofibrato y un estabilizador de superficie; en donde el estabilizador de superficie se selecciona entre el grupo que consiste en hipromelosa, docusato sódico, laurilsulfato sódico, hidroxipropilcelulosa SL, un copolímero aleatorio de acetato de vinilo y vinil pirrolidona, y sus combinaciones. Reivindicación 2: La composición de acuerdo con la reivindicación 1, caracterizada porque además comprende: (iii) celulosa microcristalina silicificada; (iv) uno o más agentes de relleno o diluyentes seleccionados entre el grupo que consiste en almidones, lactosa, sacarosa, glucosa, manitol, ácido silícico; (v) crospovidona; y (vi) estearato de magnesio.Claim 1: A pharmaceutical composition of fenofibrate for oral administration, characterized in that it comprises: (i) fenofibrate nanoparticles having an average effective particle size of less than 300 nm; (ii) a surface stabilizer adsorbed on the surface of the fenofibrate nanoparticles; wherein the fenofibrate nanoparticles are present in an amount of 99.5% to 0.001% by weight, based on the total combined weight of the fenofibrate nanoparticles and a surface stabilizer; wherein the surface stabilizer is present in an amount selected between 0.5% and 99.999% by weight, based on the total combined dry weight of the fenofibrate nanoparticles and a surface stabilizer; wherein the surface stabilizer is selected from the group consisting of hypromellose, sodium docusate, sodium lauryl sulfate, hydroxypropylcellulose SL, a random copolymer of vinyl acetate and vinyl pyrrolidone, and combinations thereof. Claim 2: The composition according to claim 1, characterized in that it further comprises: (iii) silicified microcrystalline cellulose; (iv) one or more fillers or diluents selected from the group consisting of starches, lactose, sucrose, glucose, mannitol, silicic acid; (v) crospovidone; and (vi) magnesium stearate.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38329402P | 2002-05-24 | 2002-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111501A2 true AR111501A2 (en) | 2019-07-24 |
Family
ID=38170635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101422A AR111501A2 (en) | 2002-05-24 | 2017-05-24 | PHARMACEUTICAL COMPOSITION OF PHENOFIBRATE AND METHOD TO PREPARE IT |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR111501A2 (en) |
| ZA (1) | ZA200410209B (en) |
-
2004
- 2004-12-17 ZA ZA200410209A patent/ZA200410209B/en unknown
-
2017
- 2017-05-24 AR ARP170101422A patent/AR111501A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200410209B (en) | 2006-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2526092T3 (en) | Olanzapine formulations in injectable nanoparticles | |
| HRP20210208T1 (en) | Pharmaceutical composition and administrations thereof | |
| NZ620887A (en) | A novel formulation of diclofenac | |
| CO6150127A2 (en) | FLIBANSERINE FORMULATIONS AND METHOD TO MANUFACTURE THEM | |
| JP2018507200A5 (en) | ||
| NZ621802A (en) | A novel formulation of meloxicam | |
| HRP20192026T4 (en) | Tablet formulations of neratinib maleate | |
| MX2014001101A (en) | 17-hydroxyprogesterone ester-containing oral compositions and related methods. | |
| MX2008000099A (en) | Modified release pharmaceutical compositions on the basis of two polymers and processes thereof. | |
| NZ599069A (en) | Methods for the Preparation of Biologically Active Compounds in Nanoparticulate Form | |
| AR054238A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING A BIGUANIDA AND A DERIVATIVE OF TIAZOLIDINDIONA | |
| AR055090A1 (en) | A PHARMACEUTICAL PRESENTATION OF A MODIFIED LIBERATION DOSAGE FORM INCLUDING AN INHIBITOR OF THE CYCLOOXYGENASE ENZYME | |
| NZ604055A (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate | |
| MX2017016823A (en) | 17-hydroxyprogesterone ester-containing oral compositions and related methods. | |
| JP2016513625A5 (en) | ||
| CO6270217A2 (en) | GALENIC FORMULATIONS OF ALISQUIRENO AND VALSARTAN | |
| ES2721849T3 (en) | Solid oral form with a double release profile comprising multiparticles | |
| CA2687491A1 (en) | Extended release formulation of nevirapine | |
| JP2008201711A (en) | Cysteine odor-reduced solid preparation | |
| JP5162141B2 (en) | Film coating composition | |
| AR111501A2 (en) | PHARMACEUTICAL COMPOSITION OF PHENOFIBRATE AND METHOD TO PREPARE IT | |
| JP2012041293A (en) | Intraoral collapsible tablet containing lactobacillus or extracted ingredient thereof | |
| RU2014115289A (en) | PAZOPANIBA COMPOSITION | |
| US20210393638A1 (en) | Novel formulation and treatment methods | |
| JP2009507850A5 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |